Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, will present multiple clinical trial results for deucrictibant, their oral bradykinin B2 receptor antagonist for treating hereditary angioedema (HAE), at the upcoming 2025 US HAEA National Summit in Baltimore.
The presentations include six poster sessions scheduled for July 11, covering long-term safety and efficacy data from the CHAPTER-1 and RAPIDe-2 extension studies, quality of life improvements, CHAPTER-3 Phase 3 trial design, durability of response, and comparison with standard of care. All posters will be available on the company's investor relations website.
Pharvaris (Nasdaq: PHVS), un'azienda biofarmaceutica in fase avanzata, presenterà diversi risultati di studi clinici su deucrictibant, il loro antagonista orale del recettore della bradichinina B2 per il trattamento dell'angioedema ereditario (HAE), al prossimo 2025 US HAEA National Summit a Baltimore.
Le presentazioni includeranno sei sessioni poster previste per l'11 luglio, che copriranno dati di sicurezza ed efficacia a lungo termine dagli studi di estensione CHAPTER-1 e RAPIDe-2, miglioramenti nella qualità della vita, il disegno dello studio di Fase 3 CHAPTER-3, la durata della risposta e il confronto con lo standard di cura. Tutti i poster saranno disponibili sul sito web delle relazioni con gli investitori della società.
Pharvaris (Nasdaq: PHVS), una compañía biofarmacéutica en etapa avanzada, presentará múltiples resultados de ensayos clínicos sobre deucrictibant, su antagonista oral del receptor B2 de bradicinina para el tratamiento del angioedema hereditario (HAE), en la próxima 2025 US HAEA National Summit en Baltimore.
Las presentaciones incluyen seis sesiones de póster programadas para el 11 de julio, que cubrirán datos de seguridad y eficacia a largo plazo de los estudios de extensión CHAPTER-1 y RAPIDe-2, mejoras en la calidad de vida, el diseño del ensayo de Fase 3 CHAPTER-3, la durabilidad de la respuesta y la comparación con el estándar de atención. Todos los pósteres estarán disponibles en el sitio web de relaciones con inversores de la empresa.
Pharvaris (나스닥: PHVS)는 후기 단계의 바이오제약 회사로, 유전성 혈관부종(HAE) 치료를 위한 경구용 브라디키닌 B2 수용체 길항제인 deucrictibant의 여러 임상 시험 결과를 다가오는 2025 US HAEA National Summit에서 발표할 예정입니다. 장소는 볼티모어입니다.
발표 내용에는 7월 11일에 예정된 여섯 개의 포스터 세션이 포함되며, CHAPTER-1 및 RAPIDe-2 연장 연구의 장기 안전성 및 효능 데이터, 삶의 질 개선, CHAPTER-3 3상 시험 설계, 반응 지속성, 표준 치료와의 비교 등이 다뤄집니다. 모든 포스터는 회사의 투자자 관계 웹사이트에서 확인할 수 있습니다.
Pharvaris (Nasdaq : PHVS), une société biopharmaceutique en phase avancée, présentera plusieurs résultats d'essais cliniques pour deucrictibant, son antagoniste oral des récepteurs B2 de la bradykinine pour le traitement de l'angio-œdème héréditaire (HAE), lors du prochain 2025 US HAEA National Summit à Baltimore.
Les présentations comprendront six sessions de posters prévues le 11 juillet, couvrant les données de sécurité et d'efficacité à long terme des études d'extension CHAPTER-1 et RAPIDe-2, les améliorations de la qualité de vie, le design de l'essai de phase 3 CHAPTER-3, la durabilité de la réponse et la comparaison avec le traitement standard. Tous les posters seront disponibles sur le site internet des relations investisseurs de la société.
Pharvaris (Nasdaq: PHVS), ein Biopharmaunternehmen in der späten Entwicklungsphase, wird mehrere klinische Studienergebnisse zu deucrictibant, ihrem oralen Bradykinin-B2-Rezeptor-Antagonisten zur Behandlung des hereditären Angioödems (HAE), auf dem bevorstehenden 2025 US HAEA National Summit in Baltimore präsentieren.
Die Präsentationen umfassen sechs Poster-Sessions, die für den 11. Juli geplant sind und Langzeit-Sicherheits- und Wirksamkeitsdaten aus den Verlängerungsstudien CHAPTER-1 und RAPIDe-2, Verbesserungen der Lebensqualität, das Studiendesign der Phase-3-Studie CHAPTER-3, Dauerhaftigkeit der Wirkung sowie einen Vergleich mit der Standardbehandlung abdecken. Alle Poster werden auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
Insights
Pharvaris to present comprehensive data on deucrictibant for HAE at major conference, signaling progression toward potential market approval.
Pharvaris's upcoming data presentations at the US HAEA National Summit represent a significant milestone in the company's clinical development program for deucrictibant. The company will present six separate posters covering both prophylactic (preventative) and on-demand treatment approaches for hereditary angioedema (HAE).
The data package is notably comprehensive, featuring long-term safety and efficacy results from two extension studies: CHAPTER-1 (prophylaxis) and RAPIDe-2 (on-demand treatment). Extension studies are particularly valuable as they demonstrate a drug's durability of effect and long-term safety profile – critical factors for chronic conditions like HAE where patients require lifelong management.
What stands out is the breadth of efficacy measurements being presented. Beyond the standard attack reduction metrics, Pharvaris is showcasing quality-of-life improvements and durability of response data, suggesting confidence in deucrictibant's holistic clinical profile. The inclusion of a propensity score-matched analysis comparing deucrictibant to standard of care treatments indicates the company is positioning its therapy against existing options – a necessary step toward market adoption.
The presentation of the CHAPTER-3 Phase 3 trial design signals Pharvaris's progression toward pivotal registration studies. Phase 3 trials represent the final stage before potential regulatory submission, indicating the company's confidence in its development program to date. Deucrictibant's oral administration offers a potential advantage over existing injectable HAE therapies, potentially addressing a significant unmet need in this rare disease market.
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland.
Details of the presentations are as follows:
- Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
Presenter: Michael E. Manning, M.D.
Format: Poster Presentation, #22
Date, time: Friday, July 11, 12:30-13:30 ET - Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study
Presenter: Michael E. Manning, M.D.
Format: Poster Presentation, #20
Date, time: Friday, July 11, 12:30-13:30 ET - Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
Presenter: H. Henry Li, M.D., Ph.D.
Format: Poster Presentation, #5
Date, time: Friday, July 11, 12:30-13:30 ET - Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
Presenter: Marc A. Riedl, M.D., M.S.
Format: Poster Presentation, #23
Date, time: Friday, July 11, 12:30-13:30 ET - Title: Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacks
Presenter: Joshua S. Jacobs, M.D.
Format: Poster Presentation, #9
Date, time: Friday, July 11, 12:30-13:30 ET - Title: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis
Presenter: Mark D. Scarupa, M.D.
Format: Poster Presentation, #7
Date, time: Friday, July 11, 12:30-13:30 ET
The posters will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.
Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com
FAQ
When and where will Pharvaris (PHVS) present its HAE clinical trial data in 2025?
What clinical trial results will Pharvaris (PHVS) present for deucrictibant?
Who are the key presenters for Pharvaris (PHVS) at the 2025 HAEA Summit?
Where can investors access Pharvaris (PHVS) presentation materials?
